SGLT2 inhibitors and cancer: why further evidence is required
- 898 Downloads
KeywordsBladder Canagliflozin Cancer Dapagliflozin Empagliflozin EMPA-REG Gastrointestinal Meta-analysis SGLT1 SGLT2
Sodium–glucose cotransporter 2
Duality of interest
The author declares that there is no duality of interest associated with this manuscript.
The author was the sole contributor to this paper.
- 1.Tang H, Dai Q, Shi W, Zhai S, Song Y, Han J (2017) SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. Diabetologia. https://doi.org/10.1007/s00125-017-4370-8
- 3.US Food and Drug Administration (2016) FDA briefing document: Endocrine and Metabolic Drug Advisory Committee meeting. Available from www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM508422.pdf. Accessed 31 August 2017
- 5.Lin H-W, Tseng C-H (2014) A review on the relationship between SGLT2 inhibitors and cancer. Int J Endocrinol. https://doi.org/10.1155/2014/719578
© Springer-Verlag GmbH Germany 2017